Entrada, Vertex in Pact on Therapeutics for Myotonic Dystrophy

 Global collaboration includes ENTR-701, Entrada’s late-stage preclinical candidate for the treatment of DM1 -

- Company’s cash runway extended into the second half of 2025 -

Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 and closing of the Company’s previously announced strategic collaboration and license agreement with Vertex.

https://finance.yahoo.com/news/entrada-therapeutics-closes-agreement-vertex-120000358.html